MedTrace Logo

Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer

NCT05367440 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 174

Last updated 2025-12-08

No results posted yet for this study

Summary

This study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of AZD5305 when given in combination with new hormonal agents (NHAs) in patients with Metastatic Prostate Cancer.

Conditions

Interventions

DRUG

AZD5305

Patients will receive an oral dose of AZD5305 once daily

DRUG

Enzalutamide

Patients will receive an oral dose of Enzalutamide once daily

DRUG

Abiraterone Acetate

Patients will receive an oral dose of Abiraterone Acetate once daily

DRUG

Darolutamide

Patients will receive an oral dose of Darolutamide twice daily

DRUG

Apalutamide

Patients will receive an oral dose of Apalutamide once daily

Sponsors & Collaborators

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
130 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-02
Primary Completion
2031-04-11
Completion
2031-04-11
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Italy
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05367440 on ClinicalTrials.gov